Role of First-Line Anti- @entity470 Therapy Compared With Anti- @entity7 Therapy in Advanced XXXX : A Meta-Analysis of Randomized Clinical Trials.

@entity1 @entity7 @entity470 @entity984 @entity7097 @entity14 @entity1349
BACKGROUND: Monoclonal antibodies targeting @entity470 ( @entity470 ) or @entity7 ( @entity7 ) have demonstrated efficacy in combination with chemotherapy in the first-line therapy of advanced @entity14 ( @entity14 ). Data from randomized studies comparing these monoclonal antibodies as initial therapy is conflicting, and their comparative efficacy remains unclear. We aimed to evaluate the impact of these targeted therapies on @entity1 outcomes by combining the data from randomized clinical trials. MATERIALS AND METHODS: MEDLINE, PubMed, EMBASE, and meeting proceedings within the past 12 months were searched to identify relevant studies. All randomized phase II/III clinical trials of advanced @entity14 comparing an anti- @entity470 therapy with an anti- @entity7 agent in the first-line setting were included. Data were extracted on sample size, objective response rate (ORR), progression-free survival (PFS), and @entity1349 ( @entity1349 ). RESULTS: Three randomized studies comprising 2014 @entity1 were included in the meta-analysis. For @entity1 with @entity984 wild type ( @entity984 - @entity7097 ) @entity14 , the ORR was superior in @entity1 who received first-line anti- @entity470 therapy compared with those who received anti- @entity7 therapy (odds ratio [OR], 1.31; 95% confidence interval [CI], 1.09-1.58; P  = .004). This effect was even stronger for all RAS- @entity7097 @entity1 (OR, 1.46; 95% CI, 1.13-1.90; P  = .004). There was no difference in PFS overall irrespective of the @entity984 - @entity7097 (HR, 1.03; 95% CI, 0.93-1.13; P  = .61) or all RAS- @entity7097 (HR, 0.92; 95% CI, 0.71-1.18; P  = .50) status. The @entity1349 was significantly longer in the @entity1 who received first-line anti- @entity470 therapy compared with those who received anti- @entity7 therapy ( @entity984 - @entity7097 : HR, 0.79; 95% CI, 0.65-0.97; P  = .026; all RAS- @entity7097 : HR, 0.77; 95% CI, 0.63-0.95; P  = .016). CONCLUSION: The results of our research show superior ORR and @entity1349 with first-line anti- @entity470 therapy compared with anti- @entity7 therapy in both @entity984 - @entity7097 and all RAS- @entity7097 @entity1 with advanced @entity14 . These results suggest that anti- @entity470 monoclonal antibodies may be a real alternative to anti- @entity7 therapy as initial treatment of advanced @entity14 .
